NCT01728519View on ClinicalTrials.gov

Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

July 31, 2012

Conditions
Allergic RhinitisAllergy
Interventions
DRUG

AllerT SC

AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)

DRUG

AllerT ID

AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)

DRUG

Placebo SC

Placebo subcutaneous injections on days 1, 7, 14, 21 and 56

DRUG

Placebo ID

Placebo intra-dermal injections on days 1, 7, 14, 21 and 56

Trial Locations (1)

1005

Lausanne University Hospital, Lausanne

Sponsors

Lead Sponsor

Anergis
All Listed Sponsors
lead

Anergis

INDUSTRY

NCT01728519 - Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen | Biotech Hunter | Biotech Hunter